Pharmacokinetic study of continuous-infusional 5-FU for esophageal carcinoma

Pharmacokinetic study of continuous-infusional 5-FU for esophageal carcinoma - Pharmacokinetic study of 5-FU for esophageal carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036566

Enrollment

Registered

2019-04-21

Start date

2019-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are planned for treatment with neoadjuvant FP therapy (CDDP 80mg/m2 + 5-FU 800mg/m2)

Exclusion criteria

Exclusion criteria: Presence of pleural effusion or ascites at registration

Design outcomes

Primary

Measure	Time frame
Distribution of area under the time-concentration couve (AUC) of 5-FU	—

Secondary

Measure	Time frame
Correlation of AUC and 5-FU related efficacy and adverse events Gender difference on AUC	—

Countries

Japan

Contacts

Public ContactKazuaki Matsui

Keio University, School of Medicine Department of Surgery

k.matsui@keio.jp0353633802

Outcome results